Olubukola M. Abiona - Concepedia

Author

Olubukola M. Abiona

National Institutes of Health ORCID

Also Known As

Abiona, Olubukola M., McLellan, Jason S., Mulligan M.J., Olubukola Abiona, Olubukola M. Abiona

Publications

15.6K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases University of North Carolina at Chapel Hill The University of Texas at Austin Frederick National Laboratory for Cancer Research

About

Olubukola M. Abiona is an author at National Institutes of Health specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	3.3K
2	Engineering	1	1	72
3	Natural Sciences	1	1	1K
4	Allergy	1	1	60
5	Biomolecular Engineering	1	1	72

Olubukola M. Abiona

Publications

15.5K

Citations

H-Index

Page 1

	Year	Citations
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Science	2020	9.7K
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist, Nature VaccinationPrototype Pathogen PreparednessVaccine DevelopmentImmunologyVirology	2020	1.6K
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, New England Journal of Medicine	2020	1.1K
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Novel BetacoronavirusViral DiagnosticsSynthetic VirologyImmunologyViral Pathogenesis	2020	1K
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett, Science Translational Medicine	2021	484
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates Kizzmekia S. Corbett, Martha Nason, Britta Flach, Science VaccinationVaccinologyMrna-1273 VaccineViral ReplicationVaccine Development	2021	322
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants Lingshu Wang, Tongqing Zhou, Yi Zhang, Science	2021	212
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett,	2020	173
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist,	2020	142
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone Baoshan Zhang, Cara W. Chao, Yaroslav Tsybovsky, Scientific Reports	2020	124

Page 1